The Only Specialized Global Intellectual Property News Agency
A Member of Talal Abu-Ghazaleh Organization

banner

BioInvent Granted a Patent in Europe for the Immune-oncology Antibody BI-505

16-Mar-2016 | Source : AG-IP News | Visits : 4641
LUND, Sweden – BioInvent International (BINV) announced today in a press release that the European Patent Office, EPO, has decided to grant the company’s patent EP 1 960 432, relating to the immune-oncology antibody BI-505. BioInvent plans to shortly initiate a Phase II trial with BI-505 in patients with multiple myeloma, with the aim to prevent or significantly delay relapse of this serious form of hematologic cancer.

The European patent for BI-505 will enter into force on 6 April 2016 and will expire in 2026. Corresponding patents have already been granted in the US, Japan, Australia, China, South Korea and Russia, among other countries.
”The extended geographical patent protection for BI-505 increases the value of our project and underlines BioInvent’s ability to develop innovative and unique antibodies against severe cancer diseases”, said Michael Oredsson, CEO of BioInvent.

During 2016, the start of clinical studies for three of BioInvent’s clinical phase drug projects are planned. In addition to the study mentioned above with BI-505, clinical studies are also expected to be initiated with BI-1206 in patients with non-Hodgkin lymphoma and chronic lymphatic leukaemia, and with TB-403 for treatment of rare but serious types of cancer in children.
 
BioInvent International AB develops immune oncology drugs. With one of the world’s largest antibody libraries, and a unique, proprietary discovery method, BioInvent can identify the optimal cellular targets and antibodies for the treatment of various tumor types.
 
BI-505 is a human antibody against ICAM-1 developed by BioInvent, which will be clinically tested in cooperation with researchers at Penn Medicine as an immuno-oncological therapy to prevent or delay relapse in patients with multiple myeloma (a form of bone marrow cancer) undergoing stem-cell transplantation. Preclinical data indicates improved activity against myeloma when BI-505 is administered in combination with Velcade® or Revlimid®. BI-505’s favourable safety profile has been demonstrated in a previous phase I trial. This and the unique mechanism of action, “flagging” remaining myeloma cells for elimination by actively recruited macrophages, as well as the potential to inhibit ICAM-1 dependent survival signals between myeloma cells and tumor stroma, indicate a unique possibility of improving the therapeutic effect of stem-cell transplantation.
 
 
share



Related Articles